Related Articles
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival
Cetuximab as salvage monotherapy in chemotherapy‑refractory metastatic colorectal cancer: A single‑center report
Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta‑analysis
Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
Multicenter phase II study of infusional 5‑fluorouracil (5‑FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first‑line treatment in patients with metastatic colorectal cancer (CELINE trial)